Addex Therapeutics Ltd. (ADXN)
Data as of , from SEC Form 4 filings.
No open-market insider trades (90d)Watch ADXN
See up to 3 months of ADXN. The 7-day demo opens the 1M and 3M ranges and puts ADXN on your watchlist.
Start 7-day demoLatest ADXN insider trades
About Addex Therapeutics Ltd. (ADXN)
The SEC lists Addex Therapeutics Ltd. under CIK 0001574232, in pharmaceutical preparations. It is grouped with Health Care companies on this site.
ADXN Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 22 | 26,522,939 | |
| Derivative transaction | 22 | 26,522,939 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
ADXN insider transactions (Form 4)
448 Form 4 filings on record, the earliest from Sep 4, 2026, newest first.
| Traded | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Lenaic Nathanael Teyssedou - Officer | Derivative | Stock-option (Right to Buy) | 37,770 | $0.00 | - | |
| Lenaic Nathanael Teyssedou - Officer | Grant or award | Stock-option (Right to Buy) | 37,770 | $0.00 | - | |
| Lenaic Nathanael Teyssedou - Officer | Derivative | Stock-option (Right to Buy) | 59,530 | $0.00 | - | |
| Lenaic Nathanael Teyssedou - Officer | Grant or award | Stock-option (Right to Buy) | 59,530 | $0.00 | - | |
| Lenaic Nathanael Teyssedou - Officer | Derivative | Stock-option (Right to Buy) | 10,000 | $0.00 | - | |
| Lenaic Nathanael Teyssedou - Officer | Grant or award | Stock-option (Right to Buy) | 10,000 | $0.00 | - | |
| Lenaic Nathanael Teyssedou - Officer | Derivative | Stock-option (Right to Buy) | 30,000 | $0.00 | - | |
| Lenaic Nathanael Teyssedou - Officer | Grant or award | Stock-option (Right to Buy) | 30,000 | $0.00 | - | |
| Lenaic Nathanael Teyssedou - Officer | Derivative | Stock-option (Right to Buy) | 65,620 | $0.00 | - | |
| Lenaic Nathanael Teyssedou - Officer | Grant or award | Stock-option (Right to Buy) | 65,620 | $0.00 | - | |
| Lenaic Nathanael Teyssedou - Officer | Derivative | Stock-option (Right to Buy) | 90,529 | $0.00 | - | |
| Lenaic Nathanael Teyssedou - Officer | Grant or award | Stock-option (Right to Buy) | 90,529 | $0.00 | - | |
| Lenaic Nathanael Teyssedou - Officer | Derivative | Stock-option (Right to Buy) | 208,974 | $0.00 | - | |
| Lenaic Nathanael Teyssedou - Officer | Grant or award | Stock-option (Right to Buy) | 208,974 | $0.00 | - | |
| Lenaic Nathanael Teyssedou - Officer | Derivative | Stock-option (Right to Buy) | 100,485 | $0.00 | - | |
| Lenaic Nathanael Teyssedou - Officer | Grant or award | Stock-option (Right to Buy) | 100,485 | $0.00 | - | |
| Mikhail Kalinichev - Officer | Derivative | Common Stock | 306,765 | $0.00 footnote F1 | - | |
| Mikhail Kalinichev - Officer | Grant or award | Common Stock | 306,765 | $0.00 footnote F1 | - | |
| Mikhail Kalinichev - Officer | Derivative | Stock-option (Right to Buy) | 200,000 | $0.00 | - | |
| Mikhail Kalinichev - Officer | Grant or award | Stock-option (Right to Buy) | 200,000 | $0.00 | - | |
| ||||||
| Jason Raleigh Nunn - Director | Derivative | Common Stock | 219,561 | $0.00 footnote F1 | - | |
| Jason Raleigh Nunn - Director | Grant or award | Common Stock | 219,561 | $0.00 footnote F1 | - | |
| Jason Raleigh Nunn - Director | Derivative | Stock-option (Right to Buy) | 50,000 | $0.00 | - | |
| Jason Raleigh Nunn - Director | Grant or award | Stock-option (Right to Buy) | 50,000 | $0.00 | - | |
| ||||||
| Roger Mills - Officer | Derivative | Common Stock | 392,837 | $0.00 footnote F1 | - | |
| Roger Mills - Officer | Grant or award | Common Stock | 392,837 | $0.00 footnote F1 | - | |
| Roger Mills - Officer | Derivative | Stock-option (Right to Buy) | 50,000 | $0.00 | - | |
| Roger Mills - Officer | Grant or award | Stock-option (Right to Buy) | 50,000 | $0.00 | - | |
| ||||||
 Isaac Manke - Director | Derivative | Common Stock | 219,561 | $0.00 footnote F1 | - | |
| Isaac Manke - Director | Grant or award | Common Stock | 219,561 | $0.00 footnote F1 | - | |
| Isaac Manke - Director | Derivative | Stock-option (Right to Buy) | 50,000 | $0.00 | - | |
| Isaac Manke - Director | Grant or award | Stock-option (Right to Buy) | 50,000 | $0.00 | - | |
| ||||||
| Vincent Michael Lawton - Director | Derivative | Common Stock | 2,507,487 | $0.00 footnote F1 | - | |
| Vincent Michael Lawton - Director | Grant or award | Common Stock | 2,507,487 | $0.00 footnote F1 | - | |
| Vincent Michael Lawton - Director | Derivative | Stock-option (Right to Buy) | 501,598 | $0.00 | - | |
| Vincent Michael Lawton - Director | Grant or award | Stock-option (Right to Buy) | 501,598 | $0.00 | - | |
| ||||||
| Raymond George Hill - Director | Derivative | Common Stock | 1,365,532 | $0.00 footnote F1 | - | |
| Raymond George Hill - Director | Grant or award | Common Stock | 1,365,532 | $0.00 footnote F1 | - | |
| Raymond George Hill - Director | Derivative | Stock-option (Right to Buy) | 273,107 | $0.00 | - | |
| Raymond George Hill - Director | Grant or award | Stock-option (Right to Buy) | 273,107 | $0.00 | - | |
| ||||||
| Timothy Mark Dyer - Officer | Derivative | Common Stock | 16,413,787 | $0.00 footnote F1 | - | |
| Timothy Mark Dyer - Officer | Grant or award | Common Stock | 16,413,787 | $0.00 footnote F1 | - | |
| Timothy Mark Dyer - Officer | Derivative | Stock-option (Right to Buy) | 3,369,796 | $0.00 | - | |
| Timothy Mark Dyer - Officer | Grant or award | Stock-option (Right to Buy) | 3,369,796 | $0.00 | - | |
| ||||||
ADXN insider trading FAQ
What is the latest insider trade for ADXN?
Addex Therapeutics Ltd. (ADXN) had 8 insider filings in the last 90 days, with the most recent on 4 September 2026. The full record for ADXN runs to 8 Form 4 filings, the earliest from 4 September 2026. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying ADXN stock?
No insider purchases of ADXN were filed in the last 90 days.
How many insiders are selling ADXN stock?
No insider sales of ADXN were filed in the last 90 days.
Where can I see ADXN SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects ADXN Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
8The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Lenaic Nathanael Teyssedou view on EDGAR
- - Mikhail Kalinichev view on EDGAR
- - Jason Raleigh Nunn view on EDGAR
- - Roger Mills view on EDGAR
- - Isaac Manke view on EDGAR
- - Vincent Michael Lawton view on EDGAR
- - Raymond George Hill view on EDGAR
- - Timothy Mark Dyer view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Insider activity in Health Care
- Where ADXN's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow ADXN with a 7-day demo
- ADXN on your watchlist
- Every ADXN Form 4 filing on record
- Up to 3 months of ADXN price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
